LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Millennium Management LLC

Millennium Management LLC increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 96.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,081 shares of the medical instruments supplier's stock after purchasing an additional 47,250 shares during the period. Millennium Management LLC owned approximately 0.43% of LeMaitre Vascular worth $8,853,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LMAT. Smartleaf Asset Management LLC grew its holdings in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC lifted its position in LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 117 shares in the last quarter. KBC Group NV boosted its stake in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares during the last quarter. Huntington National Bank increased its holdings in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after purchasing an additional 455 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth $150,000. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This represents a 26.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer now owns 1,827,003 shares in the company, valued at $155,477,955.30. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,009 shares of company stock worth $8,721,836. Insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent analyst reports. Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Lake Street Capital lifted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of "Moderate Buy" and an average price target of $98.14.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $0.73 during midday trading on Friday, reaching $81.80. The stock had a trading volume of 22,849 shares, compared to its average volume of 208,381. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The stock has a 50-day moving average of $84.02 and a 200-day moving average of $92.11. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 44.70, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.44 earnings per share. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.